We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Acute interstitial nephritis related to immune checkpoint inhibitors.
- Authors
Belliere, Julie; Meyer, Nicolas; Mazieres, Julien; Ollier, Sylvie; Boulinguez, Serge; Delas, Audrey; Ribes, David; Faguer, Stanislas
- Abstract
<bold>Background: </bold>Immune checkpoint inhibitors (anti-PD1 or anti-CTLA-4) are increasingly used in various cancers. Immune checkpoint inhibitors (ICI)-related renal disorders are poorly described (9 cases) and were only related to Ipilimumab.<bold>Methods: </bold>Retrospective collection of clinical charts of all the patients admitted for renal disorders following ICI in the University Hospital of Toulouse (France).<bold>Results: </bold>We report on adverse renal events that occurred in three patients treated with anti-PD1 (nivolumab or pembrolizumab) or anti-CTLA-4 (ipilimumab). Acute kidney injury occurred at 4-12 weeks after initiation of treatment, and harbored features of tubulo-interstitial nephritis (interstitial polymorphic inflammatory infiltrate with predominant CD3+ CD4+ T cells, associated with granuloma in one). Following withdrawal of ICI and steroid intake, estimated glomerular-filtration rate had improved in all patients.<bold>Conclusions: </bold>These data suggest that all ICI can lead to acute interstitial nephritis, possibly related to the presence of autoreactive clonal T cells. We recommend that patients receiving ICI should undergo renal monitoring every 2 weeks for 3-6 months.
- Publication
British Journal of Cancer, 2016, Vol 115, Issue 12, p1457
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/bjc.2016.358